NCT02704052View on ClinicalTrials.gov

Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

October 31, 2018

Conditions
Deep Venous ThrombosisPulmonary EmbolusVenous Thromboembolism
Interventions
DRUG

Real time enoxaparin dose adjustment

Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.

DRUG

Standard enoxaparin dose

Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.

Trial Locations (1)

84132

University of Utah Hospitals, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02704052 - Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose | Biotech Hunter | Biotech Hunter